The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.
The method, called negative enrichment, protects DNA regions of interest prior to degrading the surrounding DNA, making the target fragments easier to read.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
